Rituximab

Anupama Borker, Narendra Choudhary

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Rituximab is a chimeric mouse-human monoclonal antibody against the CD 20 antigen on the surface of B lymphocytes. It binds to CD20 and causes B cell death by antibody dependant cell-mediated cytotoxicity, complement mediated cytotoxicity and apoptosis. It leads to rapid and sustained depletion of B cells. It is licensed for use in adults with CD20 positive B-cell lymphoma and rheumatoid arthritis. In children, it has been used in a variety of off-label indications with promising results. It has proved useful as salvage therapy in relapsed refractory non-Hodgkin's lymphoma and leukemia, and in hematological conditions including chronic immune thrombocytopenic purpura, hemophilia with inhibitors, and autoimmune hemolytic anemia. It has also proved effective in autoimmune conditions like primary systemic vasculitis and systemic lupus erythematosis. Nephrotic syndrome and opsoclonus-myoclonus syndrome are among the emerging indications for rituximab. In solid organ transplantation, rituximab is useful in the prevention and treatment of acute and chronic rejection as well as in post transplantation lymphoproliferative disease. Toxicity includes acute infusion reactions, susceptibility to bacterial infections, and reactivation of viral infections.

Original languageEnglish
Pages (from-to)627-632
Number of pages6
JournalIndian Pediatrics
Volume48
Issue number8
DOIs
Publication statusPublished - 01-08-2011
Externally publishedYes

Fingerprint

B-Lymphocytes
Opsoclonus-Myoclonus Syndrome
CD Antigens
Autoimmune Hemolytic Anemia
Systemic Vasculitis
Salvage Therapy
Idiopathic Thrombocytopenic Purpura
Hemophilia A
Nephrotic Syndrome
Organ Transplantation
B-Cell Lymphoma
Virus Diseases
Bacterial Infections
Non-Hodgkin's Lymphoma
Rheumatoid Arthritis
Leukemia
Cell Death
Transplantation
Monoclonal Antibodies
Apoptosis

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Borker, A., & Choudhary, N. (2011). Rituximab. Indian Pediatrics, 48(8), 627-632. https://doi.org/10.1007/s13312-011-0098-6
Borker, Anupama ; Choudhary, Narendra. / Rituximab. In: Indian Pediatrics. 2011 ; Vol. 48, No. 8. pp. 627-632.
@article{0535579ec8c74258bfbbe0b2535e5dcb,
title = "Rituximab",
abstract = "Rituximab is a chimeric mouse-human monoclonal antibody against the CD 20 antigen on the surface of B lymphocytes. It binds to CD20 and causes B cell death by antibody dependant cell-mediated cytotoxicity, complement mediated cytotoxicity and apoptosis. It leads to rapid and sustained depletion of B cells. It is licensed for use in adults with CD20 positive B-cell lymphoma and rheumatoid arthritis. In children, it has been used in a variety of off-label indications with promising results. It has proved useful as salvage therapy in relapsed refractory non-Hodgkin's lymphoma and leukemia, and in hematological conditions including chronic immune thrombocytopenic purpura, hemophilia with inhibitors, and autoimmune hemolytic anemia. It has also proved effective in autoimmune conditions like primary systemic vasculitis and systemic lupus erythematosis. Nephrotic syndrome and opsoclonus-myoclonus syndrome are among the emerging indications for rituximab. In solid organ transplantation, rituximab is useful in the prevention and treatment of acute and chronic rejection as well as in post transplantation lymphoproliferative disease. Toxicity includes acute infusion reactions, susceptibility to bacterial infections, and reactivation of viral infections.",
author = "Anupama Borker and Narendra Choudhary",
year = "2011",
month = "8",
day = "1",
doi = "10.1007/s13312-011-0098-6",
language = "English",
volume = "48",
pages = "627--632",
journal = "Indian Pediatrics",
issn = "0019-6061",
publisher = "Springer India",
number = "8",

}

Borker, A & Choudhary, N 2011, 'Rituximab', Indian Pediatrics, vol. 48, no. 8, pp. 627-632. https://doi.org/10.1007/s13312-011-0098-6

Rituximab. / Borker, Anupama; Choudhary, Narendra.

In: Indian Pediatrics, Vol. 48, No. 8, 01.08.2011, p. 627-632.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Rituximab

AU - Borker, Anupama

AU - Choudhary, Narendra

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Rituximab is a chimeric mouse-human monoclonal antibody against the CD 20 antigen on the surface of B lymphocytes. It binds to CD20 and causes B cell death by antibody dependant cell-mediated cytotoxicity, complement mediated cytotoxicity and apoptosis. It leads to rapid and sustained depletion of B cells. It is licensed for use in adults with CD20 positive B-cell lymphoma and rheumatoid arthritis. In children, it has been used in a variety of off-label indications with promising results. It has proved useful as salvage therapy in relapsed refractory non-Hodgkin's lymphoma and leukemia, and in hematological conditions including chronic immune thrombocytopenic purpura, hemophilia with inhibitors, and autoimmune hemolytic anemia. It has also proved effective in autoimmune conditions like primary systemic vasculitis and systemic lupus erythematosis. Nephrotic syndrome and opsoclonus-myoclonus syndrome are among the emerging indications for rituximab. In solid organ transplantation, rituximab is useful in the prevention and treatment of acute and chronic rejection as well as in post transplantation lymphoproliferative disease. Toxicity includes acute infusion reactions, susceptibility to bacterial infections, and reactivation of viral infections.

AB - Rituximab is a chimeric mouse-human monoclonal antibody against the CD 20 antigen on the surface of B lymphocytes. It binds to CD20 and causes B cell death by antibody dependant cell-mediated cytotoxicity, complement mediated cytotoxicity and apoptosis. It leads to rapid and sustained depletion of B cells. It is licensed for use in adults with CD20 positive B-cell lymphoma and rheumatoid arthritis. In children, it has been used in a variety of off-label indications with promising results. It has proved useful as salvage therapy in relapsed refractory non-Hodgkin's lymphoma and leukemia, and in hematological conditions including chronic immune thrombocytopenic purpura, hemophilia with inhibitors, and autoimmune hemolytic anemia. It has also proved effective in autoimmune conditions like primary systemic vasculitis and systemic lupus erythematosis. Nephrotic syndrome and opsoclonus-myoclonus syndrome are among the emerging indications for rituximab. In solid organ transplantation, rituximab is useful in the prevention and treatment of acute and chronic rejection as well as in post transplantation lymphoproliferative disease. Toxicity includes acute infusion reactions, susceptibility to bacterial infections, and reactivation of viral infections.

UR - http://www.scopus.com/inward/record.url?scp=80755125397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755125397&partnerID=8YFLogxK

U2 - 10.1007/s13312-011-0098-6

DO - 10.1007/s13312-011-0098-6

M3 - Review article

VL - 48

SP - 627

EP - 632

JO - Indian Pediatrics

JF - Indian Pediatrics

SN - 0019-6061

IS - 8

ER -

Borker A, Choudhary N. Rituximab. Indian Pediatrics. 2011 Aug 1;48(8):627-632. https://doi.org/10.1007/s13312-011-0098-6